二、本次解禁限售股的基本情况 非公开发行核准情况 2022 年 6 月 13 日，中国证券监督管理委员会出具《关于核准山东新华医 疗器械股份有限公司非公开发行股票的批复》（证监许可[2022]1223 号），核准 公司非公开发行不超过 121,928,427 股新股，发生转增股本等情形导致总股本 发生变化的，可相应调整本次发行数量；该批复自核准发行之日起 12 个月内 有效。 中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 非公开发行股票限售股解禁上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为山东新华医疗器械股份有限公司（以下简称"新华医疗"、"公司"）非公 开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所股票上市规则》和《上海证券交易所上市公司自律监管指引第 11 号——持 续督导》等相关法律法规的要求，对新华医疗非公开发行股票限售股解禁上市流 通事项进行了审慎核查，具体核查情况及核查意见如下： 一、本次限售股上市类型 本次上市流通的限售股类型为非公开发行限售股。 | 序 | 发行对象名称 | 获配股数 | 锁定期 | | ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2023-055 山东新华医疗器械股份有限公司 非公开发行限售股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为非公开发行股份；股票认购方式为网下，上市股数为 36,936,027 股。 本次股票上市流通总数为 36,936,027 股。 本次股票上市流通日期为 2023 年 8 月 28 日。 一、本次限售股上市类型 （一）非公开发行核准情况 2022 年 6 月 13 日，中国证券监督管理委员会出具《关于核准山东新华医疗器 械股份有限公司非公开发行股票的批复》（证监许可[2022]1223 号），核准公司非 公开发行不超过 121,928,427 股新股，发生转增股本等情形导致总股本发生变化 的，可相应调整本次发行数量；该批复自核准发行之日起 12 个月内有效。（详见 公司于 2022 年 6 月 17 日披露的《山东新华医疗器械股份有限公司关于非公开发 行股票申请获得中国证监会核准批复的公告》，编号：临 2022- ...

证券代码：600587 证券简称：新华医疗 公告编号：临2023-054 山东新华医疗器械股份有限公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所股票上市规则》、《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求》和《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等有关规定，山东新华医疗器械股份有限公司(以下简 称"公司"或"新华医疗")就截至 2023 年 6 月 30 日募集资金存放与使用情况 进行了审慎核查，并出具说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准山东新华医疗器械股份有限公司非公 开发行股票的批复》（证监许可[2022]1223 号）核准，新华医疗非公开发行人民 币普通股（A 股）54,900,098 股，募集资金总额为人民币 1,283,564,291.24 元， 扣除各项不含税发行费用人民币 7,325,377.45 元后，实际 ...

山东新华医疗器械股份有限公司独立董事 关于第十一届董事会第二次会议相关议案的独立意见 根据《公司法》、《证券法》、《上市公司独立董事规则》和《上海证券交易所股 票上市规则》以及《山东新华医疗器械股份有限公司公司章程》(以下简称"《公司 章程》")等相关规定,我们作为山东新华医疗器械股份有限公司(以下简称"公司") 的独立董事,在认真审阅了公司董事会提供的相关议案和资料的基础上,现基于独 立判断的立场,对公司第十一届董事会第二次会议相关议案发表如下独立意见: 一、关于公司度募集资金存放与使用情况的专项报告议案的独立意见 公司严格按照《上市公司监管指引第 2 号-上市公司募集资金管理和使用的监 管要求》《上海证券交易所上市公司自律监管指引第 1号 -- 规范运作》等法律法 规的相关规定,规范、合理地使用募集资金,对募集资金进行了专户存储和专户使 用,并及时履行了相关信息披露义务,不存在变相改变募集资金用途和损害股东利 益的情况,不存在违规使用募集资金的情形。公司编制的募集资金存放与使用情况 专项报告真实、准确地反映了公司 2022年上半年募集资金存放与使用的相关情况。 独立董事签字: 顾维军 (以下无正文) (此 ...

山东新华医疗器械股份有限公司 第十一届董事会第二次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 一、董事会会议召开情况 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）第十 一届董事会第二次会议于 2023 年 8 月 11 日以书面或通讯方式通知全体董事，据 此通知，会议于 2023 年 8 月 21 日在公司三楼会议室召开。会议以现场与通讯相 结合的方式召开，会议应到董事 11 名，实到 11 名，公司监事和高级管理人员列 席了会议，会议由董事长王玉全先生主持，会议程序符合《公司法》和《公司章 程》的规定。 二、董事会会议审议情况 （一）审议通过《公司 2023 年半年度报告全文及摘要》 证券代码：600587 证券简称：新华医疗 编号：临 2023-052 表决结果：同意 11 票，反对 0 票，弃权 0 票。 （二）审议通过《关于公司 2023 年半年度募集资金存放与使用情况的专项 报告的议案》 公司 2023 年半年度募集资金存放与使用情况符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 ...

证券代码：600587 证券简称：新华医疗 编号：临 2023-053 山东新华医疗器械股份有限公司 第十一届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、 误导性陈述或者重大遗漏负连带责任。 一、监事会会议召开情况 山东新华医疗器械股份有限公司（以下简称公司）第十一届监事会第二次会 议于 2023 年 8 月 1 日以通讯和书面方式发出通知，据此通知，会议于 2023 年 8 月 21 日在公司三楼会议室召开，应到监事 3 名，实到 3 名。会议由监事会主席 牟乐海先生召集和主持，符合《公司法》和《公司章程》规定。 2、2023 年半年度报告的内容和格式符合中国证监会和上海证券交易所的 各项规定，所包含的信息能从各方面真实地反映出公司当年度的经营管理和财务 状况等事项； 3、在公司监事会提出本意见前，未发现参与 2023 年半年度报告编制和审 议的人员有违反保密规定的行为； 1 4、因此，我们保证，公司 2023 年半年度报告内容真实、准确和完整，承 诺其中不存在任何虚假记载、误导性陈述或重大遗漏，并对其内容真实性、准确 性和完整性承担个别及连带责任。 表 ...

Financial Performance - Total operating revenue for Q1 2023 reached ¥2,438,890,277.93, representing a 15.42% increase compared to ¥2,112,972,293.22 in Q1 2022[11] - Net profit attributable to shareholders for Q1 2023 was ¥196,511,980.14, a significant increase of 54.01% from the previous year's ¥127,600,000[11] - The net profit after deducting non-recurring gains and losses was ¥183,670,392.01, reflecting a 23.75% increase year-over-year[11] - Basic earnings per share for Q1 2023 were ¥0.46, up 48.39% from ¥0.31 in Q1 2022[11] - Net profit for Q1 2023 reached ¥202,032,967.27, compared to ¥129,776,153.67 in Q1 2022, marking an increase of about 55.8%[31] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥16,134,620.03, showing a remarkable increase of 104.57% compared to the same period last year[11] - The cash inflow from operating activities was CNY 2,677,674,550.70, an increase of 5.4% compared to CNY 2,540,053,632.68 in Q1 2022[35] - The net cash flow from operating activities was CNY 16,134,620.03, a significant improvement from a negative CNY 353,160,624.57 in the same period last year[35] - The cash outflow for purchasing goods and services decreased to CNY 1,833,717,572.07 from CNY 2,004,044,670.26, reflecting a reduction of approximately 8.5%[35] - Cash inflow from financing activities increased significantly to CNY 1,618,114,291.24, compared to CNY 694,069,268.00 in the previous year, marking a growth of approximately 133.3%[36] Assets and Liabilities - Total assets as of the end of Q1 2023 amounted to ¥14,329,504,437.67, a 10.64% increase from ¥12,951,981,234.86 at the end of the previous year[13] - The company's total liabilities decreased to ¥7,049,282,720.17 from ¥7,162,680,947.62, a reduction of approximately 1.6%[28] - The total equity attributable to shareholders rose to ¥6,878,350,191.11, up from ¥5,393,129,480.26, reflecting an increase of around 27.6%[28] - Cash and cash equivalents amounted to approximately 2.72 billion yuan, up from 1.69 billion yuan at the end of 2022[26] - Inventory increased to ¥3,080,408,088.29 from ¥3,028,718,658.95, showing a growth of about 1.7%[27] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 20,300[16] - The largest shareholder, Shandong Yiyang Health Industry Development Group, holds 28.90% of shares[19] - The company reported no significant changes in shareholder relationships or actions during the reporting period[20] Research and Development - Research and development expenses for Q1 2023 were ¥73,557,725.07, an increase from ¥54,260,023.18 in Q1 2022[11] Fair Value Changes - The company reported a fair value change gain of ¥18,316,041.72 in Q1 2023, compared to a loss of ¥21,070,476.47 in the same period last year[11] - Net profit attributable to shareholders rose by 54.01%, driven by increased operating revenue and fair value changes of certain stocks[15] Other Financial Metrics - Long-term borrowings increased to ¥119,266,409.44 from ¥96,326,409.44, representing a growth of about 23.8%[28] - The company's contract assets rose to ¥110,129,035.02 from ¥98,631,827.22, an increase of approximately 11.5%[27] - The total non-current assets increased to ¥5,781,873,341.28 from ¥5,566,967,093.96, reflecting a growth of about 3.9%[27] - The net cash flow from investing activities was negative CNY 139,927,754.81, worsening from negative CNY 64,632,017.25 in Q1 2022[36] - The ending balance of cash and cash equivalents reached CNY 2,507,326,131.84, a substantial increase from CNY 1,147,806,980.50 at the end of Q1 2022[36]

关于召开 2022 年度暨 2023 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 18 日(星期四) 上午 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： 证券代码：600587 证券简称：新华医疗 公告编号：临 2023-032 山东新华医疗器械股份有限公司 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 5 月 11 日(星期四) 至 5 月 17 日(星期三)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2023 年 3 月 31 日发布公司 2022 年年度报告、2023 年 4 月 28 日发布公司 2023 年第一季度报 告，为便于广大投资者 ...

Financial Performance - In 2022, the company's operating revenue was approximately CNY 9.28 billion, a decrease of 2.11% compared to CNY 9.48 billion in 2021[44]. - The net profit attributable to shareholders was CNY 502.61 million, down 9.68% from CNY 556.49 million in the previous year[44]. - The net profit after deducting non-recurring gains and losses increased by 31.47% to CNY 505.35 million, compared to CNY 384.38 million in 2021[44]. - The company's cash flow from operating activities decreased by 72.33% to CNY 388.05 million, down from CNY 1.40 billion in 2021[44]. - Basic earnings per share decreased by 10.22% to CNY 1.23, down from CNY 1.37 in 2021[50]. - The weighted average return on net assets was 9.68%, a decrease of 2.29 percentage points from 11.97% in the previous year[50]. - Total assets at the end of 2022 were approximately CNY 12.95 billion, an increase of 11.52% from CNY 11.61 billion at the end of 2021[44]. - The company's net assets attributable to shareholders increased by 9.73% to CNY 5.39 billion, compared to CNY 4.91 billion at the end of 2021[44]. Research and Development - In 2022, the company's R&D expenses amounted to 401.27 million yuan, representing a year-on-year increase of 35.58%[4]. - The company launched 56 R&D projects, including 4 national and provincial projects, and achieved 21 new patent applications, demonstrating a strong commitment to innovation[92]. - The company applied for 257 patents and software copyrights, with 317 patents granted, including 12 invention patents[63]. - The company has established multiple provincial-level R&D platforms and has participated in over 20 national key R&D projects, receiving numerous provincial and municipal technology advancement awards[117]. - The company plans to enhance its technology innovation system and increase R&D investment during the "14th Five-Year Plan" period[131]. Product Development and Innovation - The company is actively developing new product lines, including medical endoscopes and high-end infusion products, with substantial progress in the development phase[9]. - The company has developed the world's first peracetic acid low-temperature sterilizer and the first domestic high-energy medical linear accelerator, showcasing its innovation capabilities[89]. - The company achieved breakthroughs in R&D projects, including the first high-energy medical electronic linear accelerator and BFS equipment in Shandong Province, and established the first intelligent disinfection supply center in the country[101]. - The company has launched 14 comprehensive solutions and a "mobile PCR cabin laboratory" to align with national policies and enhance customer engagement[8]. Market and Sales Strategy - The company has established a nationwide marketing network and after-sales service system, ensuring rapid response and service capabilities[16]. - The company is actively expanding its sales channels, combining online and offline strategies to increase market influence and customer satisfaction[95]. - The company is focusing on international expansion, with international revenue reaching new heights[67]. - The company established overseas offices in Vietnam and Egypt in 2022, contributing to a steady increase in international trade revenue and marking a new chapter in its international strategy[105]. - The company aims to strengthen its market presence by focusing on high-end customers and enhancing product quality, with a particular emphasis on the domestic replacement trend[196]. Financial Management and Investments - The company successfully raised CNY 1.284 billion through a non-public offering of up to 121,928,427 shares, with a subscription multiple of 4.84 times excluding the controlling shareholder[62]. - The company plans to enhance its main business by increasing R&D investment and expanding into new fields and markets[185]. - The company aims to improve operational efficiency by identifying core and target areas in both existing and new business segments[185]. - The company has implemented a refined assessment system to enhance profitability, leading to significant improvements in gross profit margins across various business segments[75]. Awards and Recognition - The company received multiple awards for its products, including the "China Design Intelligence Award" for its "Smart CSSD Overall Solution" and "Shandong Province's First Set of Technical Equipment" for two products[130]. - The company obtained the first FDA market authorization for the MOST-T steam sterilizer, marking it as the first domestic sterilization equipment company to receive this certification, enhancing its brand influence globally[104]. Operational Efficiency - The production efficiency of endoscopic instruments improved by 36.50% due to the implementation of five-axis automated processing upgrades[9]. - The company emphasizes digital transformation in after-sales service management to enhance operational efficiency and customer resource integration[18]. - The company is focusing on intelligent manufacturing and product structure upgrades through a non-public offering, aiming to enhance production capacity and improve profitability[100].

证券代码：600587 证券简称：新华医疗 公告编号：临 2022-064 山东新华医疗器械股份有限公司 关于参加"山东辖区上市公司 2022 年度投资者网上集体 接待日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，构建和谐投资者关系，山东新华医疗器 械股份有限公司（以下简称"公司"或"新华医疗"）将参加由中国证券监督管 理委员会山东监管局、山东省上市公司协会等单位联合举办的"山东辖区上市公 司 2022 年度投资者网上集体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过网上平台采取网络远程的方式举 行，投资者可登录全景网"投资者关系互动平台"（ http://ir.p5w.net）参与 公司本次投资者网上集体接待日活动，活动交流时间为 2022 年 11 月 16 日 （星期三）14:00-16:00。 届时公司副总经理、董事会秘书李财祥先生、公司财务总监周娟娟女士及证 券事务代表李静女士将通过网络在线交流问答的形式，与投资者进行沟通和交流， 欢迎 ...